According to a new report by Polaris Market Research, the global psoriasis drug market was valued at USD 22.63 billion in 2025 and is projected to reach USD 56.96 billion by 2034, expanding at a CAGR of 10.80% over the forecast period. The market is estimated at USD 24.99 billion in 2026. Growth is underpinned by the rising global prevalence of psoriasis, expanding adoption of biologic and biosimilar therapies, and accelerating investment in precision dermatology and AI-assisted drug development across key end-use industries.

What Is Driving Psoriasis Drug Market Growth?

Demand is climbing as the growing global burden of psoriasis converges with rapid advances in biologic and biosimilar therapies. An estimated 125 million people worldwide live with the condition, according to the International Federation of Pharmaceutical Manufacturers and Associations, sustaining a large and expanding pool of patients seeking effective treatment. Manufacturers and clinicians are prioritizing targeted immune-pathway therapies, pushing psoriasis drug adoption across dermatology and rheumatology practices worldwide. Polaris analysts note that interleukin-17 inhibitors have shown improvements of up to 90% on the Psoriasis Area and Severity Index in clinical studies, positioning the segment for sustained double-digit growth through 2034, with hospital pharmacies emerging as the largest revenue contributor and retail pharmacies posting steady incremental gains.

Key Trends Shaping the Psoriasis Drug Industry

AI-Enabled Drug Discovery and Trial Design

Artificial intelligence is improving psoriasis drug discovery by analyzing clinical, genetic, and biomarker data to identify new drug targets, supporting a broader technology advancement wave across the industry. Machine learning tools are also being used to predict how individual patients will respond to specific therapies and to streamline clinical trial recruitment and safety-signal detection.

Biosimilar Expansion and Regulatory Momentum

Regulatory approvals for novel biologics and biosimilars continue to expand the treatment landscape. In June 2026, AbbVie received European Commission approval extending SKYRIZI (risankizumab) to children and adolescents aged six and older with moderate-to-severe plaque psoriasis, reflecting a broader regulatory landscape that is widening patient access to advanced therapies.

Oral Targeted Therapies and Competitive Innovation

A wave of next-generation oral therapies is reshaping the competitive landscape. In March 2026, Johnson & Johnson secured U.S. FDA approval for ICOTYDE (icotrokinra), an interleukin-23 receptor antagonist delivered as a targeted oral peptide, giving patients aged 12 and older a systemic alternative to injectable biologics and signaling a positive market outlook for oral innovation.

Market Segmentation: Breaking Down the Psoriasis Drug Market

Polaris segments the psoriasis drug market by class, treatment, route of administration, distribution channel, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Class

The interleukin inhibitors segment led the market in 2025, accounting for 38.9% of revenue and also registering the fastest growth rate, on the strength of high efficacy and a targeted mechanism of action in moderate-to-severe psoriasis. Tumor necrosis factor (TNF) inhibitors, vitamin D analogues, and corticosteroids remain important for mild-to-moderate cases and combination regimens.

By Treatment

Biologics remain the dominant treatment category, capturing 62.8% of 2025 revenue and posting the fastest growth as well, driven by their advanced mechanism of action and expanding biosimilar access. Systemic and topical treatments continue to serve patients with milder disease or a preference for non-injectable options, signaling where near-term demand around targeted oral therapies is shifting.

Read More @ https://www.polarismarketresearch.com/industry-analysis/global-psoriasis-drug-market

By Route of Administration

The parenteral route holds the largest share, reflecting the widespread use of injectable biologics, and is projected to expand at the fastest CAGR of 11.2% through 2034 as patient-friendly delivery systems such as pre-filled syringes and auto-injectors gain traction. Oral and topical routes remain relevant for milder cases and for patients who prefer noninvasive options.

By Distribution Channel

Hospital pharmacies captured the largest share in 2025 and are also growing fastest, reflecting their central role in dispensing biologics and managing moderate-to-severe cases. Retail pharmacies remain significant for topical and oral therapies, while online and other channels are gaining gradual traction as digital health infrastructure matures.

Regional Outlook: Where Is the Psoriasis Drug Market Growing Fastest?

North America led the market in 2025 with a 44.5% share, on the back of high psoriasis prevalence, advanced healthcare infrastructure, and strong biologic adoption, while Asia Pacific is expected to post the fastest CAGR of 10.6% through 2034, driven by rising prevalence and expanding healthcare access in densely populated countries. Within North America, the United States remains the largest single market; within Asia Pacific, China is a primary growth engine alongside India. Europe rounds out the top three, supported by robust healthcare systems and strong biologics and biosimilars research activity in Germany, the UK, and France.

Competitive Landscape: Leading Psoriasis Drug Companies

Key players profiled in the report include AbbVie Inc., Johnson & Johnson Services, Inc., Novartis AG, and Amgen Inc., alongside Eli Lilly and Company, AstraZeneca plc, UCB S.A., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Pfizer Inc., LEO Pharma A/S, Biogen Inc., Dr. Reddy's Laboratories, and Takeda Pharmaceutical Company Limited, who are focusing on label expansions, biosimilar development, and pipeline partnerships to strengthen market position across the interleukin-inhibitor and biologics segments outlined above. Recent moves include AbbVie's European Commission approval extending SKYRIZI to pediatric patients and Johnson & Johnson's FDA approval of ICOTYDE, both aimed at deepening share in North America and Europe.

Why It Matters for Buyers Evaluating Psoriasis Drug Market Entry

For stakeholders researching the psoriasis drug market forecast, this report benchmarks market share, segment-level pricing, and forecast data — by class, treatment, route of administration, distribution channel, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking oral targeted therapies as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

japan ophthalmic spectacle lenses and equipment market

Graphene-Enhanced Conductive Polymers Market

Virtual Data Room Market

Monoclonal Antibodies In Veterinary Health Market

AI in Drug Repurposing Market

Revenue Cycle Management Market

Carboxy Therapy Market

Sealing and Strapping Packaging Tapes Market

Fatty Acid Esters Market